Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.

Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.

<h4>Background</h4>During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Heimo Lagler, Katharina Grabmeier-Pfistershammer, Veronique Touzeau-Römer, Selma Tobudic, Michael Ramharter, Judith Wenisch, Guido Andrés Gualdoni, Monika Redlberger-Fritz, Theresia Popow-Kraupp, Armin Rieger, Heinz Burgmann
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2012
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/738ef5870b3140ce8bcd14c42c4134ec
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/738ef5870b3140ce8bcd14c42c4134ec

Similar Items